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Abstract
Problem: The overuse of antibiotics has created antimicrobial resistance (AMR)
resulting in treatment failure for bacterial infections. To combat AMR, clinicians should
only prescribe antibiotic therapy when clinically warranted. It is easy to misdiagnose a
viral infection. However, any delay in the initiation of antibiotic therapy in a bacterial
infection may lead to increased morbidity and mortality. These patients with non-specific
clinical symptoms may be misdiagnosed without a rapid and definitive diagnostic test.
Methods: This quality improvement (QI) initiative utilized an evidence-based clinical
guideline for procalcitonin (PCT) levels for antibiotic therapy de-escalation. WBC counts
were collected two-days and one-day before ID work-up along with PCT levels and white
blood cell (WBC) counts collected on day-1, day-3, and day-5 post infectious disease.
Data was collected via prospective chart review including the number of positive PCT
levels obtained versus positive cultures, average length of antibiotic use, number of
different antibiotics used, and the time until the bacterial infection was confirmed or
denied.
Results: The implemented PCT clinical guideline allowed for faster identification of
bacterial infections than standard blood cultures. There is significant evidence supporting
a positive relationship between elevated PCT levels and positive cultures. Over time the
level of PCT decreases showing a correlation with a reduction of the WBC count.
Implications for Practice: Use of the PCT clinical guideline can identify whether there
is a bacterial infection rapidly allowing for the initiation or de-escalation of antibiotic
therapy preventing further AMR resistance.
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Initiation of Procalcitonin Screening as a Marker in Antibiotic Therapy De-escalation
Overview
The increase in bacterial resistance to antibiotics is a global health concern
(Ventola, 2015). In 1928 Alexander Fleming discovered the first antibiotic- penicillin,
radically affecting treatment and mortality rates of many diseases such as pneumonia,
gonorrhea, and rheumatic fever. Over the last nine decades, more than 100 different
antibiotics were developed, resulting in increased cure rates of bacterial infections.
However, through overuse of antibiotics in the healthcare system and the agricultural
industry this has created antimicrobial resistance (AMR) resulting in treatment failure for
bacterial infections (Carlet et al., 2014). Additionally, there are significant barriers to the
creation and discovery of new antibiotics.
One major barrier to the development of new antibiotics is cost. Antibiotics take
years to develop and generally have a limited time of effectiveness before resistance
develops. In recent years there has been greater AMR seen in gram-negative bacteria
(Gandra, Barter, & Laxminarayan, 2014). Increasing AMR has led to higher rates of
morbidity and mortality in addition to the increasing economic costs to the patient
(Gandra, Barter, & Laxminarayan, 2014). Therefore, pharmaceutical companies have
begun focusing development efforts and financial resources towards alternative
medications. The high cost of AMR is measured in more than just financial losses.
The Centers for Disease Control and Prevention (CDC) reports that two million
Americans become ill with AMR diseases every year resulting in a minimum of 23,000
deaths. Further, the CDC estimates that the cost of AMR is $55 billion annually, with $20
billion in health care expenditures and $30 billion in productivity losses. (Dadgostar,
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2019). The increasing rate of AMR is a world-wide situation that has forced
governmental and non-governmental agencies to implement protocols guiding
appropriate antibiotic use (Carlet et al., 2014).
In order to combat the costly issue of AMR, clinicians should only prescribe
antibiotic therapy when clinically warranted. In fact, it is easy to misdiagnose a viral
infection; furthermore, any delay in the initiation of antibiotic therapy for a bacterial
infection may lead to increased morbidity and mortality (Bayram et al., 2015). Patients
with non-specific clinical symptoms may be easily misdiagnosed without a rapid and
definitive diagnostic test.
The gold standard for diagnosing bacterial infections is through use of blood
cultures. Unfortunately, there is a minimum of 48 to 72 hours before definitive growth
can identify the organism. This results in a delay of two to three days before the correct
antibiotic can be initiated. Using a blood test that measures procalcitonin (PCT) would
enhance care and allow health care providers to determine if an infection is bacterial
possibly much sooner than blood cultures.
PCT is an inactive protein of the hormone calcitonin. PCT production is triggered
by the detectability of the inflammatory response within two to four hours of onset of
production. Production is suppressed unless there is an active bacterial infection in the
body (Shiferaw, 2016). Due to its long half-life of 25-30 hours, PCT has greater
advantages as a biomarker over the active form- calcitonin- with a short half-life.
Therefore, PCT is a superior biomarker. Due to the predictability of its half-life and
observable level in lab testing, PCT has implications for initiation and cessation of
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antibiotics resulting in a reduction of AMR, morbidity, mortality, and healthcare costs
(Shiferaw, 2016).
Purpose Statement
The purpose of this QI project was to evaluate the use of an evidence-based
clinical guideline for PCT levels for antibiotic therapy de-escalation. The implemented
clinical guideline was done at a long-term acute care hospital (LTACH) in a Midwestern
state. Patients in LTACHs are at an increased risk of bacterial infections such as urinary
tract infections and pneumonia. Current protocol is to obtain two sets of blood cultures, a
urinalysis with reflex culture and a sputum culture when patients clinical picture changes
(deviates). Based upon clinical picture, laboratory values, and clinician judgement,
patients may be started on antibiotic therapy or a “wait and watch” approach may be
taken until culture results return. The use of a PCT value along with clinical picture, vital
signs, and a complete blood count may help the clinician to determine if antibiotics are
warranted. The use of PCT could help to limit unnecessary exposure to antibiotic therapy
and limit potential adverse reactions. Reduction in the use of antibiotics leads to
organizational benefits which ultimately benefit the patient as well, such as the ability to
reallocate scarce resources, reduction of hospital length of stay, and increase cost savings.
A question was used to guide the literature review: What was the effect of using PCT as a
diagnostic marker to identify bacterial infections in adult patients ages 18 and above?
Literature Review
The Cumulative Index of Nursing and Allied Health Literature (CINAHL),
PubMed and Medline (EBSCO), Cochrane and Consumer Health Complete were
searched. Key search terms used were procalcitonin AND biomarker AND bacterial
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infections resulting in 1,643 articles. The search was refined to include peer reviewed
journals, randomized controlled trials (RCT), systematic reviews, meta-analyses, and
research articles in English from 1/1/2014 to 1/1/2021. Studies prior to 2014 were
excluded. Inclusion criteria included studies consisting of male and female gender
patients who were 18 years of age or older in an acute care hospital. Exclusion criteria
included male or female under the age of 18 who were not in-patient at an acute care
hospital. Duplicates were removed leaving 273 full text articles. Review of abstracts was
done to ensure inclusion criteria were met. This resulted 36 articles. Full text articles
were reviewed, resulting in 10 articles selected for inclusion in this literature review.
Bayram et al. (2015) investigated procalcitonin values and soluble triggering
receptors that were expressed on myeloid cells-1 (sTREM-1) to be able to differentiate
sepsis from noninfectious systemic inflammatory response syndrome (NI-SIRS). This
enables clinicians to monitor the progression of those with sepsis. The study used a
prospective data collection from 74 patients (41 individuals with NI-SIRS and 33 with
sepsis) hospitalized in Celal Bayar University Hospital, Mansia, Turkey during an
undisclosed timeframe. Blood was obtained from sepsis patients on days 0, 3, 4, 7, and 14
and then from NI-SIRS patients on days 0 and 3 (Bayram et al, 2015). Blood cultures
revealed, gram-negative bacteria were the leading cause of sepsis in 60.6% of the cases
(Bayram et al, 2015). The overall mortality rate equaled 18 patients in the sepsis group,
these patients were divided between two units—ICU and surgical ward. The mortality
occurrence was 16 and two patients respectively. The NI-SIRS group the mortality rate
was nine patients (Bayram et al, 2015). Hence, the differentiation determined mortality
early on by pointing out the sepsis v non-sepsis group.
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Based upon the sepsis-related organ failure assessment (SOFA) scores,
procalcitonin and sTREM-1 markers were evaluated to differentiate sepsis from NI-SIRS
cases (Bayram et al, 2015). PCT and sTREM-1 markers results were higher in sepsis than
NI-SIRS patients on days 0 and 3. Receiver operating characteristic (ROC) analysis was
completed based upon SOFA scores, PCT, and sTREM-1 markers in the differentiation
of sepsis and NI-SIRS. PCT and sTREM-1 values were not as significant as SOFA values
in the prognosis in the early stages of sepsis. PCT was significant after day seven and
sTREM-1 value after day four (Bayram et al, 2015). It was found that SOFA scores, PCT
and sTREM-1 levels were significantly higher in patients with sepsis than in NI-SIRS
patients (Bayram et al, 2015). PCT and sTREM-1 were important predictors in the
outcomes of patients with sepsis. To be able to make an early diagnosis and the likely
prognosis of patients suspected to have sepsis the researchers found that it requires serial
monitoring of PCT and sTREM-1 values (Bayram et al, 2015).
Like the previous study, Jain et al. (2014) conducted a prospective observational
study to determine if a PCT level could be used as an indicator of 28-day mortality rate of
critically ill patients with suspected sepsis. The study took place in the Medical Intensive
Care Unit in New Delhi, India from July 2011 to June 2013 and included 70 critically ill
patients (Jain et al., 2014). Treatment was conducted based upon the Surviving Sepsis
Campaign; antibiotic therapy guided by culture, infection source, and the healthcare
provider (Jain et al., 2014). Patients who met sepsis criteria as defined by the 2001
International Sepsis Definitions Conference were enrolled (Jain et al., 2014).
Evaluation of this study utilized the Acute Physiology and Chronic Health
Evaluation (APACHE II) score, Simplified Acute Physiology Score (SAPS II) and SOFA
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scores on day-one (Jain et al., 2014). Additionally, (PCT) and C-reactive protein (CRP)
levels on day 1, 7, and 28 following sepsis diagnosis were reviewed. Quantitative
variables at admission were compared between survivors and non-survivors with
Wilcoxon rank sum test and qualitative variables by chi-square test (Jain et al., 2014).
The PCT level was higher in patients with septic shock than severe sepsis and
sepsis (Jain et al., 2014). The level of PCT fell significantly in survivors at 28 days with
the median PCT 5.4 ng/mL on day-1 to 3.1 ng/mL on day-7 to 0.1 ng/mL on day-28.
Upon admission, elevated PCT was a superior predictor of mortality than CRP. As with
the Bayram et al. (2015) study use of serial PCT levels is recommended in conjunction
with clinical judgment with history and physical examination.
Shehabi et al. (2014) investigated the effect of a low PCT cut-off for antibiotic
therapy to correlate the relationship of PCT with the severity and mortality of sepsis. The
study used a single-blind, randomized controlled trial with 400 patients in 11 Australian
ICUs. The sample population included those who were at least 18 years of age suspected
of having either a bacterial infection or sepsis and were expected to receive antibiotics for
longer than 24 hours from March 2011 to December 2012 (Shehabi et al., 2014). The
PCT level was measured daily and based upon Australian Antibiotics Therapeutic
Guidelines and antimicrobial stewardship, antibiotics were stopped if criteria were met as
outlined by the PCT de-escalation protocol (Shehabi et al., 2014).
Analysis included 196 PCT versus 198 standard care patients, and both groups
included 93 patients with septic shock. The length of time to antibiotic initiation to
cessation between groups was compared using a log-rank test and presented as median
interquartile range (IQR) (Shehabi et al., 2014). The median IQR number of antibiotic
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treatments were 9 versus 11 days; in patients with positive sputum cultures were 11
versus 15 days; with septic shock patients 9 versus 11 days; and the overall 90-day
mortality was 35 versus 31 days, in PCT versus standard care (Shehabi et al., 2014).
Results showed decreased mortality equal to four people. This study along with the
Bayram et al. (2015) and Jain et al. (2014) provides strong evidence to show that use of
PCT decreases overall patient mortality (Shehabi et al, 2014).
Unlike the previous studies Schuetz et al. (2017) conducted a systematic review
assessing the length of antibiotic therapy with PCT monitoring in a large patient group
with differing acuity. Randomized control trials (RCT) with 6708 participants from 26
trials in 12 different countries in primary care, emergency departments, medical floors
and ICU with acute respiratory infections to receive antibiotics based on procalcitonin
levels or in a control group from February 2017 to April 201 were included (Schuetz et
al., 2017).
The systematic review showed 286 deaths in 3336 PCT-guided patients (8.6%)
compared to 336 in 3372 controls (10.0%) (Schuetz et al., 2017). There was a
significantly lower mortality with PCT-guided therapy. PCT guided therapy had a 2.4day reduction in antibiotic exposure (5.7 versus 8.1 days) with lower risk of antibiotic
related side effects. A sensitivity aggregate-data analysis of the 32 trials showed similar
results (Schuetz et al., 2017).
Huang et al. (2017) conducted a systematic review and meta-analysis examining
adult ICU patients that were managed with a PCT-guided algorithm or standard care.
Thirteen trials with 5,136 patients were included with three clinical strategies: initiation,
discontinuation, or a combination of antibiotic initiation and discontinuation strategies
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(Huang et al., 2017). Analysis revealed that the PCT-guided antibiotic discontinuation
strategy had fewer total days with antibiotics (mean = 1.66 days), longer antibiotic free
days (mean = 2.26 days) and lower short-term mortality (Huang et al., 2017).
The review recommended the use of PCT to guide antibiotic discontinuation and
reduce length of antibiotic exposure and lower short-term mortality (Huang et al., 2017).
The meta-analysis supported the use of a low PCT level to discontinue antibiotic
treatment and the use of antibiotic 1.67 days less and a lower short-term mortality
compared to standard care. However, a baseline PCT value should not be used alone to
determine antibiotic initiation. Further research is needed to determine the cut-off value
of PCT for antibiotic discontinuation and to be able to generalize across multiple
populations (Huang et al., 2017).
Townsend et al. (2018) used a PCT-guided algorithm for lower respiratory tract
infection with clinical decision making and antibiotic stewardship for earlier antibiotic
discontinuation in a 350-bed academic Baltimore, Maryland hospital. The electronic
medical records were reviewed for control patients. A 30-day follow-up assessment using
structured EMR review was conducted for both groups (Townsend et al., 2018).
Initial PCT was obtained in the emergency department then every 48 hours after
being admitted to the floor or 24 hours for those who were admitted to ICU (Townsend et
al., 2018). PCT results were only used as a guideline for discontinuation decisions.
Antibiotic discontinuation was recommended if serial PCT values fell more than 80%
from peak. In the PCT group antibiotic duration was lower than the control group with
fewer patients discharged on antibiotics (Townsend et al., 2018).
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The median antibiotic duration in the PCT (intervention) group was lower than in
the control group (5 vs 6 days), total days of antibiotic therapy was significantly lower,
and significantly fewer patients were discharged on antibiotics (37.4% vs 55.5%). There
was no significant difference in PCT and control groups for adverse outcomes at 30 days.
Hospital readmission at 30 days was 22.4% of PCT patients and 26.5% in control group.
The study found that PCT-guided antibiotic therapy did effectively shorten antibiotic
duration for LRTI (Townsend et al., 2018).
The literature review supports the concept of PCT levels as an effective diagnostic
tool in combination with clinical judgment. It further demonstrates use of PCT as a better
prognostic biomarker than CRP for bacterial infections. The use of PCT levels can limit
unnecessary antibiotic therapy and decrease potential adverse reactions and AMR.
However, PCT should not be used alone, nor should it stop the initiation of antibiotic
therapy based upon one lab result when clinical judgment supports initiation.
Based upon the literature review the use of the Plan-Do-Study-Act (PDSA)
evidence-based framework will be implemented to guide this QI project. The aim of this
project is to increase identification of bacterial infections with the addition of the PCT
test as compared to the previous infectious disease (ID) workup. Primary outcome
measures analyzed included the average antibiotic length of time, the number of
antibiotics used and the number of times elevated PCT correlated with positive blood
cultures. The QI project was implemented by the LTACH clinicians and monitored by the
primary investigator.
Methods
Design
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This QI project utilized a prospective observational design by implementing a PCT
level to the current ID workup. Quantitative data was collected via prospective chart
review and included the number of positive PCT levels obtained versus blood cultures,
urine culture, and sputum cultures. In addition, data was collected regarding the average
length of time a patient was on an antibiotic, the number of different antibiotics used and
the number of times that positive cultures correlated with an elevated PCT level.
Additionally, data collected included time until diagnosis of bacterial infection after ID
work-up was collected.
Setting
This QI project took take place in a LTACH specializing in vent-weaning, longterm antibiotic therapy, and wound care therapy. The unit averages 23 critical care
patients daily with a minimum 21-day length of stay. The hospital, located in a
midwestern state has approximately 100 employees and is part of a large system of
LTACH hospitals located throughout the United States. The hospital did not use PCT in
the ID work-up prior to project implementation.
Sample
This QI project used a purposeful sample drawn based on the ID work-up criteria.
Patients who did not meet criteria for ID work-up were excluded along with patients
younger than age 18 and not admitted to the hospital. All medical records of patients
fitting the above criteria from January 4, 2022, to March 31, 2022, were included in the
analysis. The use of a unique alphanumeric identifier was implemented to de-identify
patient data. This identifier consisted of the last name initial followed up first name initial
with the six-digit date of ID work-up (month/day/two-digit year). A master list containing
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coded identifiers and coordinating patient names with date ID work-up began was stored
on the project mentor’s password protected hospital provided computer.
Approval Processes
Formal, written approval was sought and obtained from the hospitals Critical Care
Director on October 7, 2021. and given university IRB approval in December 2021. The
project protocol was evaluated and determined be a QI project and therefore, not be
human-subjects research. Because labs were routinely drawn for each patient that met
inclusion criteria, no risk to the patient was foreseen. Potential patient benefit included
potential decreased antibiotic exposure. No ethical considerations were noted.
Data Collection/Analysis
De-identified patient data was collected prospectively from chart review.
Demographic variables included age, gender, ethnicity and admitting diagnosis. Patient
data also included PCT levels, length of antibiotic use (in days), number of antibiotics
used, urine culture results, sputum culture results, and blood culture results. Data was
analyzed using descriptive statistics for measure of central tendency and use of Wilks
Lambda analysis for test of association. SPSS Statistics was used to analyze the length of
antibiotic use, number of antibiotics used, time of identification of bacterial infection
after ID work-up, and the number of times positive PCT levels correlated to a positive
culture.
Procedure
Adding a PCT level to the current ID work-up was a QI project selected by the
Doctor of Nursing Practice (DNP) candidate in corroboration with the pulmonary critical
care Certified Nurse Specialist and was approved by the Critical Care Director. Education
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was created and distributed to all clinicians practicing in the LTACH instructing the
inclusion of a PCT level when doing an ID work-up and a PCT level again on day three
and five prior to implementation. After the project was implemented in January 2022,
PCT levels were included along with patient presentation, WBC counts two-days before
ID work-up, one-day before then again on day 1, 3, and 5 with blood/urine/sputum
culture results when evaluating the initiation/cessation of antibiotic therapy and length of
antibiotic therapy. Data collection occurred for 12 weeks after initiation of the
implementation. The data was downloaded from the EMR in April of 2022 and
transferred to an Excel spreadsheet for data analysis.
Results
Demographics
The sample included 22 patients aged 46 to 83 years, with a mean of 65.68 years
(SD=9.67) (Table 1). There were 13 females (59.09%) and nine males (41.91%)
participants (Table 1). The only ethnicity was Caucasian. The admitting diagnoses were
10 Acute hypoxic respiratory failure due to Covid pneumonia (45.45%), four Acute on
chronic hypoxic and hypercapnic respiratory failure COPD exacerbation (18.18%), two
Acute hypoxic respiratory failure after cardiac arrest (9.09%), two Acute hypoxic
respiratory failure after bowel perforation (9.09%), two Acute hypoxic respiratory failure
due to intracranial diffuse brainstem hemorrhage (9.09%), and two Acute hypoxic
respiratory failure due to Ischemic stroke (9.09%) (Table 1, Appendix C).
Procalcitonin
A one-way repeated measured analysis of variance (ANOVA) was conducted to
evaluate the null hypothesis of the effect of PCT as a diagnostic marker to identify
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bacterial infections in adult patients 18 and above. PCT was measured on day-1, day-3,
and day-5. Then WBC counts were retroactively collected two days before ID work-up,
one day before infection onset, with WBC counts collected on day-1, day-3, and day-5.
The results of the ANOVA indicated a significant time effect of WBC, (Wilks’ Lambda =
.379, F(4, 17) = 6.960, p < .01, n2 = .621). Thus, there is significant evidence to support
the positive relationship between elevated PCT levels and positive cultures (Table 4). The
results of the ANOVA indicated a significant time effect of PCT, (Wilks’ Lambda = .727,
F(2, 20) = 3.566, p < .01, n2 = .273). Hence, over time the level of PCT decreases
showing a correlation with a reduction of WBC count (Table 5).
A retrospective review of the ID work-up examined WBC counts. A reviewal
identified the mean WBC count two-days before the ID work-up of 11.224 (SD=3.5665),
one-day before with a mean of 12.867 (SD=4.7381), day-1 post ID work-up with a mean
of 17.276 (SD=7.0034), day-3 post ID work-up a with a mean of 13.305 (SD=5.1299)
and day-5 post ID work-up with a mean of 11.343 (SD=4.7777) (Table 2, Appendix A).
PCT levels were simultaneously collected with WBC counts. On day-1 post ID work-up
the mean PCT was .4752 (SD=.62030), day-3 post ID work-up with a mean of
.3371(SD=.45256), and day-5 post ID work-up with a mean of .2252 (SD=.28365) (Table
3, Appendix B). Hence, there is a correlation between both WBC and PCT levels
decreasing with the initiation of antibiotics.
Discussion
Implementation of this QI effort accomplished the purpose to increase
identification of bacterial infections with the addition of a PCT test as compared to the
previous ID work-up. The primary outcome measures analyzed included
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the average length of time patient was on antibiotics, the average number of different
antibiotics used, the average time until confirmation of bacterial infection after ID workup.
Serum PCT levels will rise within two to four hours of an inflammatory stimulus,
then peaking within 24-48 hours (Shiferaw, 2016). PCT levels then will quickly decline
at a predictable rate. After reaching the peak, levels will then decline about 50 percent
every 1 to 1.5 days. This correlation was seen in the QI project with the PCT levels
obtained from the sample population (Shiferaw, 2016).
The implemented PCT clinical guideline allowed for faster identification of
bacterial infections with a (mean=1.74 days) vs. the standard of 48-72 hours with blood
cultures. Positive cultures correlated with an elevated PCT level 14 times throughout the
QI project. The PCT and cultures were negative eight times throughout the project.
Therefore, this means that eight patients who started on antibiotics due to clinical
presentation were able to be de-escalated preventing further contribution to AMR. The
average length of time patients were on antibiotics was (mean=8.909 days) with an
average number of different antibiotics used was (mean=2.14). The use of continual
monitoring of PCT allowed to de-escalate antibiotic use when the PCT value decreased to
negative.
Implications for Practice
PCT helps to distinguish bacterial infection from other causes of infection or
inflammation. In patients with LRTIs and sepsis, PCT can be used with clinical
judgement for guiding antibiotic therapy and resolving diagnostic uncertainty. The
collection of serial PCT levels with WBC counts on day-1, day-3, and day-5 can
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determine the continual need of antibiotic therapy based upon clinical improvement and
serial PCT levels. The use of PCT as a guide for antibiotic therapy provides clinicians
with another investigative tool in the decision process for the initiation and cessation of
antibiotic therapy for patients with suspected bacterial infection. This allows for
reduction of inappropriate antibiotic use, reducing hospital admissions, decreasing length
of hospitalization, limiting potential adverse reactions, reallocation of scare resources,
and increase cost savings to a strained healthcare system and patients.
Recommendations
It is recommended that the LTACH continue with the use of a PCT level with the
current ID work-up. Then if the PCT level is positive, antibiotic initiation should occur
with repeat PCT and WBC counts on day-3 and day-5 to monitor whether antibiotic
therapy should be escalated or de-escalated. The use of PCT levels is an effective
diagnostic tool in combination with clinical judgment. The use of PCT levels can limit
unnecessary antibiotic therapy and decrease potential adverse reactions and AMR.
However, PCT should not be used alone, nor should it stop the initiation of antibiotic
therapy based upon one lab result when clinical judgment with history and physical
examination supports initiation.
It should be noted that there are limitations to this QI project due to the limited
sample size which then limited the ethnicity of the population being collected. A longer
implementation period of the QI project than 12-weeks would allow for the collection of
more data results likely increasing the population ethnicity. A larger sample size in a
bigger institution would also compensate for this limitation. The facility being a LTACH
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limits sample size as this population has hospitalization lengths ranging from 21-120
days.
Conclusion
In this QI effort, implementation of PCT levels in the ID work-up in patients aged 18years and older in an LTACH identified bacterial infections rapidly. Monitoring of serial
PCT levels allows for evaluation of antibiotic acceleration or de-escalation swiftly when PCT
levels decline. With the limited sample size of this project, future PDSA cycles and data
collection should occur to continue analysis of PCT value to antibiotic de-escalation.
This QI project exemplifies the role of the DNP in practice. The DNP is a terminal
degree, a unique merging of fundamental Nightingale principles with medical science to
improve health outcomes while fulfilling human needs . A DNP prepared provider has the
honor and responsibility to make continuous significant impact on the quality and efficiency
of the healthcare system by practicing with the best evidence-based practice. DNPs’ must
advocate for their patient by continuing to push for health policies that are in the best interest
of their patient then implementing and evaluating their effectiveness. This QI project
implemented a biomarker tool to the current ID work-up resulting in faster identification of
bacterial infections and allowing for de-escalation of antibiotics when unwarranted. Hence,
improving patient outcomes.
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Apppendices/Tables
Table 1
Demographic Characteristics of Participants, n = 22
Characteristics
Age
Gender
Female
Male
Race/Ethnicity
Caucasian
Admitting Diagnosis
Acute hypoxic resp fail 2/2 Covid pneumonia
A/C hypoxic/hypercapnic resp fail 2/2 COPD exacer.
Acute hypoxic resp fail after cardiac arrest
Acute hypoxic resp fail after bowel perforation
Acute hypoxic resp fail 2/2 intracranial diffuse brainstem
hemorrhage
Acute hypoxic respiratory failure due to Ischemic stroke

n

%

22
13
9

59.09%
40.91%

22

100%

10
4
2
2
2

45.45%
18.18%
9.09%
9.09%
9.09%

2

9.09%

M

SD

65.68

9.67

Note. Output obtained using IBM SPSS Statistics for Windows, version 27.0

Table 2
White Blood Cell Count Statistics (n=22)
WBC count 2-days before ID work-up
WBC count 1-day before ID work-up
WBC count Day-1 post ID work-up
WBC count Day-3 post ID work-up
WBC count Day-5 post ID work-up

Mean

SD

N

11.224
12.867
17.276
13.305
11.343

3.5665
4.7381
7.0034
5.1299
4.7777

22
22
22
22
22

Note. Output obtained using IBM SPSS Statistics for Windows, version 27.0
Table 3
Procalcitonin Statistics (n=22)
PCT Day-1 post ID work-up
PCT Day-3 post ID work-up
PCT Day-5 post ID work-up

Mean

SD

N

0.4752
0.3371
0.2252

0.62030
0.45256
0.28365

22
22
22

Note. Output obtained using IBM SPSS Statistics for Windows, version 27.0
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Table 4
Multivariate Tests WBCa
Effect

Value

F

Hypothesis df

Error df

Sig.

Partial Eta
Squared

Noncent. Parameter

Observed Powerc

Time Wilks’ Lambda

0.379

6.960

4.000

18.000

0.002

0.621

27.840

0.971

a.

Design: Intercept Within Subjects Design: Time.

c. Computed using alpha = 0.05

Note. Output obtained using IBM SPSS Statistics for Windows, version 27.0

Table 5
Multivariate Tests PCTa
Effect

Value

F

Hypothesis df

Error df

Sig.

Partial Eta
Squared

Noncent. Parameter

Observed Powerc

Time Wilks’ Lambda

0.727

3.366

2.000

20.000

0.048

0.273

7.131

0.590

a.

Design: Intercept Within Subjects Design: Time.

c. Computed using alpha = 0.05

Note. Output obtained using IBM SPSS Statistics for Windows, version 27.0
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Appendix C

Admitting Diagnosis

Acute hypoxic respiratory failure after cardiac arrest
Acute hypoxic respiratory failure due to Covid pneumonia
Acute on chronic hypoxic and hypercapnic respiratory failure COPD exacerbation
Acute hypoxic respiratory failure after bowel perforation
Acute hypoxic respiratory failure due to intracranial diffuse brainstem hemorrhage
Acute hypoxic respiratory failure due to Ischemic stroke

25

INITIATION OF PROCALCITONIN SCREENING

26

Appendix D

Gender

M

F

Appendix E

Time til Identification of
Bacterial Infection in hours

Procalcitonin

41.76

Culture
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Appendix F

Procalcitonin vs Culture Correlation

Positive PCT/Positive Culture

Negative PCT/Negative Culture
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